Oncotelic Therapeutics Advances Nanotechnology and AI in Drug Development
Oncotelic Therapeutics has made advancements in nanotechnology-enabled drug delivery and AI-driven biomedical infrastructure. The company was featured in an editorial published by BioMedWire highlighting its progress.
Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing its proprietary solutions focused on nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company recently received attention through an editorial published by BioMedWire, which highlighted its work.
The company is focusing on the development of its Deciparticle™ nanomedicine platform and AI-driven oncology development. Sapu Nano, with whom Oncotelic collaborates, presented the Deciparticle™ platform at the BIO International Convention 2026 in San Diego. The presentation specifically focused on Oncotelic's development of ultra-small nanoparticles.
At the BIO International Convention in late May 2026, Sapu Nano also announced the first patient dosing in a Phase 1b trial of Sapu003. Sapu003 is an intravenous Deciparticle™ formulation of everolimus. This first-in-human study evaluates weekly IV dosing of Sapu003 in patients with advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, and HCC.
Oncotelic Therapeutics released its first quarter 2026 financial results, reporting on its strategic progress. The company is a clinical-stage biotechnology firm concentrating on oncology, AI-enabled drug development, and advanced drug delivery platforms.